A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt Horses - A randomised blind study

Vaccine

Volumn 29, Issue 22, 2011, Pages 3917-3922

  Gildea, Sarah ^a   Arkins, Sean ^b   Walsh, Cathal ^c   Cullinane, Ann ^a  

^a IRISH EQUINE CENTRE   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antibody; Comparison; Equine; Influenza; Vaccine

Indexed keywords

ANTIBODY; DUVAXYN IE T PLUS; EQUENZA T; EQUILIS; EQUILIS RESEQUIN; EQUINE INFLUENZA VACCINE; EQUIP FT; INFLUENZA VACCINE; PREVAC T PRO; PROTEQFLU TE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL HUNTING; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; EQUINE HERPES VIRUS; EQUINE HERPES VIRUS TYPE 1; EQUINE HERPES VIRUS TYPE 4; EQUINE INFLUENZA; FEMALE; HORSE; IRELAND; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VACCINATION; ANIMAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HORSE DISEASE; IMMUNIZATION; IMMUNOASSAY; IMMUNOLOGY; INFLUENZA VIRUS A H3N8; METHODOLOGY; ORTHOMYXOVIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HORSE DISEASES; HORSES; IMMUNIZATION, SECONDARY; IMMUNOASSAY; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; IRELAND; MALE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 80051711279     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.003     Document Type: Article

References (28)

1. Mumford JA, Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand 1992;79:137-46.
2. Mumford JA, Jessett DM, Rollinson EA, Hannant D, Draper ME. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet Rec 1994;134(7):158-62.
3. Newton JR, Townsend HG, Wood JL, Sinclair R, Hannant D, Mumford JA. Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J 2000;32(1):65-74.
4. Mumford J. Collaborative study for the establishment of three European Pharmacopoeia Biological Reference Preparations for equine influenza horse antiserum. Pharmeuropa 2000:7-21.
5. Daly J, Daas A, Behr-Gross ME. Collaborative study for the establishment of a candidate equine influenza subtype 2 American-like strain A/EQ/South Africa/4/03-horse antiserum biological reference preparation. Pharmeuropa Bio 2007;1:7-14.
6. Newton JR, Texier MJ, Shepard MC. Modifying likely protection from equine influenza vaccination by varying dosage intervals within the Jockey Club Rules of Racing. Equine Vet Educ 2005;17:314-8.
7. Webster RG. Are equine 1 influenza viruses still present in horses? Equine Vet J 1993;25(6):537-8.
8. Cullinane A, Elton D, Mumford J. Equine influenza - surveillance and control. Influenza Other Respi Viruses 2010;4(6):339-44.
9. Mumford JA. Biology Epidemiology and Vaccinology of Equine Influenza. Quality Control of Equine Influenza Vaccines. In: Proceedings of an International Symposium organised by the European Directorate for the Quality of Medicines (EDQM). 2001. p. 7-12.
10. Daly JM, Yates PJ, Newton JR, Park A, Henley W, Wood JL, et al. Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines. Vaccine 2004;22(29-30): 4101-9.
11. OIE. Manual of Standards for Diagnostics Tests and Vaccines, Equine Influenza, Chapter 2.5.7, 875-877, 2008.
12. Heldens JG, Weststrate MW, van den Hoven R. Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines-a retrospective analysis of three independent field trials. J Immunol Methods 2002;264(1-2):11-7.
13. Newton JR, Lakhani KH, Wood JL, Baker DJ. Risk factors for equine influenza serum antibody titres in young thoroughbred racehorses given an inactivated vaccine. Prev Vet Med 2000;46(2):129-41.
14. Hannant D, Mumford JA, Jessett DM. Duration of circulating antibody and immunity following infection with equine influenza virus. Vet Rec 1988;122(6):125-8.
15. Gildea S, Arkins S, Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus. Influenza Other Respi Viruses 2010;4(6):363-72.
16. Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, Sindle T, et al. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 2007;68(2):213-9.
17. Mumford JA, Wilson H, Hannant D, Jessett DM. Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiol Infect 1994;112(2):421-37.
18. Heldens JG, Van de Wouw JC, Van Loon AA. An updated equine influenza vaccine and an equine influenza-herpesvirus combination vaccine containing an immunostim adjuvant provoke equal antibody levels in young foals throughout the primary vaccination course. Vet J 2002;164(3):288-91.
19. Paillot R, Grimmett H, Elton D, Daly JM. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 2008;39(3):21.
20. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19(December (9-10)):1180-7.
21. Edlund Toulemonde C, Daly J, Sindle T, Guigal PM, Audonnet JC, Minke JM. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 2005;156(12):367-71.
22. Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, et al. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet Immunol Immunopathol 2006;112(3-4):225-33.
23. Gildea S, Arkins S, Cullinane A. Management and environmental factors involved in Equine Influenza outbreaks in Ireland from 2007 to 2010. Equine Vet J 2010. DOI: 10.1111/j.2042-3306.2010.00333x.
24. Wood JLN. A Review of the History and Epidemiology and a Description of Recent Outbreak, [MSc Dissertation]. London: University of London; 1991.
25. Cullinane A, Weld J, Osborne M, Nelly M, McBride C, Walsh C. Field studies on equine influenza vaccination regimes in thoroughbred foals and yearlings. Vet J 2001;161(2):174-85.
26. Park AW, Wood JL, Newton JR, Daly J, Mumford JA, Grenfell BT. Optimising vaccination strategies in equine influenza. Vaccine 2003;21(21-22):2862-70.
27. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol 2010;142(Suppl 1):S102-8.
28. Larson LJ, Schultz RD. Three-year duration of immunity in dogs vaccinated with a canarypox-vectored recombinant canine distemper virus vaccine. Vet Ther 2007;8(2):101-6.